Concerto Biosciences Funding Round

11/2/2022

Venture Equity

$23,000,000

Series A

The company intends to use the funds to advance its first product through first-in-human studies, accelerate its discovery platform, and leverage the platform to expand its line of products in partnership with other companies.

Private & Independent

Biopharmaceutical

279 Harvard street Apartment 41
Cambridge, MA 02139
USA

Undisclosed

Concerto Biosciences reinvents humanity's relationship with microbes. We envision a future where each of us fine-tunes the microbial communities in us, on us, and around us to stay healthy. To pave the way, Concerto invented a platform to measure, in ultra-high throughput, how microbes behave in the presence of each other. These measurements enable Concerto to see the world as it is: a massive underlying network of microbial interactions that shapes the health of our bodies and our planet. The network reveals new products--"ensembles" of microbes that work in concert to perform tasks that benefit people. Our first ensembles rehabilitate the skin microbiome, providing protection from previously intractable diseases like eczema and restoring health to millions.